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Abbreviations 
 
-SMA   alpha-smooth muscle actin 
CKD    chronic kidney disease 
ECM    extracellular matrix 
EMT    epithelial mesenchymal transition 
HKO    heterozygous knockout 
IL-1    interleukin-1 beta 
IL-6    interleukin-6 
LPS    lipopolysaccharide 
MCP-1   monocyte chemoattractant protein-1 
MYPT-1   myosin phosphatase target subunit-1 
ROCK    Rho-associated coiled-coil kinase 
TGF-1   transforming growth factor-beta 1 
TNF    tumor necrosis factor alpha 
UUO    unilateral ureteral obstruction 
WT    wild type 
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Chapter I 
Preface 
 
 Chronic kidney disease (CKD) is the common end-point of renal disease 
and is defined by a decline in glomerular filtration rate and by structural 
impairments of the kidney. According to the US Renal Data System 2013 
Annual Data Report, 14% of the adult population in the USA had CKD, 
and the costs for CKD patients older than 65 years were estimated at over 
45 billion dollars (1). Patients with CKD require lifelong dialysis, and the 
only curative treatment for them is kidney transplantation. CKD is a major 
burden on the healthcare system and is an important predictor of 
cardiovascular morbidity and mortality. A variety of etiologies such as 
genetic, autoimmune, infectious, environmental dietary, and medications 
eventually lead to the same features of CKD. Essentially, almost all CKD 
progression is characterized by fibrosis in either the glomerulus or the 
tubulointerstitium (2, 3). Therefore, renal fibrosis is a critical problem for 
CKD patients. 
For studying renal fibrosis, unilateral ureteral obstruction (UUO) is the 
most widely used model, given that interstitial inflammations occur rapidly 
and the subsequent histological changes are recognized. These include 
tubular dilation, tubular atrophy, and fibrosis, which are common 
alterations observed in several tubulointerstitial diseases (4-7). Many 
investigators have shown using UUO models that renal interstitial fibrosis 
is the result of failed wound healing following an initial injury. As shown in 
6 
 
Fig. 1, the pathophysiology of renal fibrosis is classified into four phases: 
1) activation and injury; 2) fibrogenic signaling; 3) fibrogenesis; and 4) 
renal destruction. Interstitial inflammation, tubular activation, and 
myofibroblast appearance are observed in the kidney in the first phase. 
Next, the myofibroblasts increase in number, and chemotaxis of fibroblasts 
and monocytes into the tubulointerstitium begins. In the third phase, 
extracellular matrix (ECM) accumulates in the injured regions. Finally, 
ECM accumulation, capillary obliteration, and tubular ischemia appear in 
the injured kidney, leading to nephron and tubule degeneration (1). 
 
 
Fig. 1. Progression of renal interstitial fibrosis 
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The small G-protein, Rho, is known to play a role as a molecular switch in 
various cellular functions, including cell contraction, adhesion, 
proliferation, differentiation, and inflammatory response (8-10). 
Rho-associated coiled-coil kinase (ROCK), a serine/threonine kinase, is a 
major downstream effector of Rho and is comprised two isoforms, ROCK1 
(Rho-kinase , ROK) and ROCK2 (Rho-kinase , ROK). In humans, 
these two kinases have 64% overall identity, 89% identity in the catalytic 
kinase domain, 55% identity in the coiled-coil region, and 80% identity in 
the pleckstrin homology (PH) domain (Fig. 2). The expression of ROCK1 
is distributed in the kidney, liver, lung, spleen, and testis, whereas ROCK2 
is expressed particularly in the heart and brain (11-13). As shown in Fig. 3 
and Fig. 4, the Rho/ROCK signaling pathway is involved in several 
diseases such as cancer, neuronal degradation, cardiovascular diseases, and 
CKD (14-26). 
 
 
 
Fig. 2. Functional domains of ROCK1 and ROCK2 
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Fig. 3. ROCK and the Rho/ROCK signal pathway. 
 
 
 
Fig. 4. Therapeutic target for cardiovascular and other diseases 
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With respect to renal interstitial fibrosis, ROCK inhibition has been 
investigated using the UUO model. The ROCK inhibitors, fasudil and 
Y27632, partially attenuate interstitial fibrosis by inhibiting the mRNA 
expression of collagen, TGF-1, and -SMA in the UUO model (27-29). 
Fasudil and Y27632 specifically inhibit ROCK, although they are 
non-selective ROCK1 and ROCK2 inhibitors. Fu, et al. showed, using 
ROCK1 knockout (KO) mice, that these mice were not protected against 
renal fibrosis either early or late after UUO compared with wild-type (WT) 
mice (30). There were no differences between the ROCK1 KO and WT 
mice in histological changes or mRNA expression of collagen and -SMA. 
However, pharmacological ROCK inhibition effectively suppresses renal 
interstitial fibrosis in the same study. Thus, given that ROCK1 does not 
contribute to the suppression of renal interstitial fibrosis by UUO, ROCK2 
may play a critical role in renal interstitial fibrosis.  
In this study, I investigated the role of ROCK2 on renal interstitial fibrosis 
induced by UUO, using ROCK2 heterozygous knockout (HKO) mice. I 
also investigated the underlying mechanisms of ROCK inhibition in renal 
interstitial fibrosis. 
 
 
  
10 
 
Chapter II 
Partial deletion of ROCK2 protein fails to reduce renal fibrosis in 
mouse unilateral ureteral obstruction model. 
 
Summary 
 
Rho/ROCK signaling is involved in renal fibrotic processes. 
Non-selective ROCK1/2 inhibitors have been reported to diminish renal 
interstitial fibrosis in the rodent UUO model. To clarify the role and 
contribution of ROCK2 in renal fibrosis, I used ROCK2 HKO mice to 
assess collagen deposition and fibrosis-related gene expression in the 
kidney of the UUO model. In the ROCK2 HKO mice, the expression level 
of ROCK2 in the normal kidney was half of that of WT mice. The 
expression of ROCK1 in both ROCK2 HKO mice and WT mice was 
equivalent. Furthermore, in the ROCK2 HKO and the WT mice, the 
hydroxyproline content and the gene expressions of collagen I and TGF-1 
in the obstructed kidneys were augmented after UUO. In contrast, the 
expression of -SMA mRNA decreased in the ROCK2 HKO mice 
compared with that in the WT mice. The ROCK activity of the obstructed 
kidneys indicated by the phosphorylation of myosin phosphatase target 
subunit-1 (MYPT-1), which is a non-selective substrate of both ROCK1 
and ROCK2, was equivalent among the ROCK2 HKO and WT mice. In 
conclusion, there was no difference in renal interstitial fibrosis and 
UUO-induced ROCK activity between the ROCK2 HKO and WT mice, 
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indicating that a genetic partial disruption of ROCK2 is insufficient in 
protecting renal fibrosis. 
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Introduction 
 
Several reports in the cardiovascular field have focused on the 
relationship between ROCK and tissue fibrosis. In a rat coronary artery 
occlusion model, the inhibition of ROCK by fasudil, a non-selective 
ROCK1/2 inhibitor, reduced the expression of inflammatory cytokines such 
as TGF-β1 and macrophage migration inhibitory factor, and prevented 
cardiomyocyte hypertrophy and interstitial fibrosis (31). Furthermore, 
fasudil attenuated the upregulation of profibrotic gene expression such as 
collagen I and III in the heart after pressure overload in the transverse 
aortic constriction (TAC) model mice, and ameliorated myocardial 
remodeling and fibrosis (32). With regard to kidney diseases, fasudil 
inhibited the activation of ROCK and the TGF-β-Smad pathway, 
preventing glomerulosclerosis and tubulointerstitial fibrosis in an 
aldosterone-induced renal injury model (33). In the UUO model, the 
inhibition of ROCK by Y-27632 or fasudil inhibited the activity of ROCK 
and gene expression of fibrosis-related factors such as collagen, TGF-1, 
and -SMA, thereby preventing tubulointerstitial fibrosis (27-29). These 
findings suggest that ROCK plays an important role in the development of 
tissue fibrosis. 
Further investigations using ROCK1 or ROCK2 KO mice have been 
recently reported. The deletion of ROCK1 suppressed cardiac fibrosis and 
ventricular remodeling after pressure overload by TAC (34) and protected 
the development of albuminuria in streptozotocin-induced diabetic kidney 
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disease model (35). In the cardiac-specific deletion of ROCK2, angiotensin 
II-induced cardiac hypertrophy and fibrosis were attenuated compared with 
that of the WT mice (36). These reports as well as previous studies of 
ROCK inhibitors suggest that both ROCK1 and ROCK2 contribute to 
cardiac inflammation and fibrosis in the development of heart failure. In 
contrast, the deletion of ROCK1 did not affect the expression of -SMA 
and collagen I and III within the diseased kidney in the UUO model and 
did not prevent UUO-induced renal fibrosis (30). Thus, the role and 
contribution of ROCK2 in renal fibrosis remains unestablished. In the 
present study, I assessed whether ROCK2 is involved in the development 
of renal fibrosis after UUO in ROCK2 HKO mice. 
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Materials and methods 
 
All animal experiments were conducted according to the Experimental 
Animal Care and Use Committee, Mitsubishi Tanabe Pharma Corporation, 
that was regulated by Management and Ethics of Animal (Law No. 105, 
1973, Japan). In addition, this study was performed according to the 
reliability standards (Article 43 of the Pharmaceutical Affairs Law 
Enforcement Regulations, Japan). 
 
Animals 
Male ROCK2 HKO (37) and WT mice were purchased from Charles 
River Japan (Charles River Laboratories International, Kanagawa, Japan), 
were maintained at room temperature on a 12-h light/dark cycle, and were 
allowed ad libitum access to standard laboratory chow (CRF-1, Oriental 
Yeast, Tokyo, Japan) and tap water. The animals were kept at the 
department animal care facility of Mitsubishi Tanabe Pharma Corporation 
in accordance with the relevant protocols.  
 
Unilateral ureteral obstruction model 
Mice were anesthetized with sevofrane (Maruishi Pharmaceutical, Osaka, 
Japan) and subjected to a left flank incision. UUO was performed by a 
complete ligation of the left ureter at the ureteropelvic junction with a 4-0 
silk suture. The sham-operated mice had their ureter exposed without 
ligation. All mice were used for experiments at 8–10 weeks of age after 1 
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week of acclimation period. Further, mice were euthanized under 
anesthesia with sevofrane on days 7 and 14 after operation. Kidneys were 
then removed and divided into several parts (for RNA, hydroxyproline, and 
protein sections). 
 
Determination of kidney hydroxyproline content 
The collagen content in the kidney was determined by hydroxyproline 
using a modified method previously described (38, 39). In brief, the 
kidneys were homogenized in phosphate buffered saline (Gibco, Life 
Technologies, Carlsbad, CA, USA) (700 ml/100 mg kidney weight), 
completely hydrolyzed in 6 mol/l HCl (Wako Pure Chemical Industries, 
Osaka, Japan) at 120°C for 6 h, and filtered through a 0.45-m Millex-HV 
filter (Merck Millipore, Hessen, Germany). The samples were dried by 
vacuum centrifugation using by EZ-2 plus (Genevac, Suffolk, UK) for 16 h. 
Dried samples were solubilized in distilled water. The samples were 
oxidized using chloramine T solution [1.4% sodium 
p-toluenesulfonchloramide trihydrate (chloramine T, Wako Pure Chemical 
Industries) and 10% n-propanol (Wako Pure Chemical Industries) in citric 
acid buffer, which was consisted of 0.26 mol/l citric acid (Sigma-Aldrich), 
0.88 mol/l sodium acetate trihydrate (Wako Pure Chemical Industries), 0.85 
mol/l sodium hydroxide (Wako Pure Chemical Industries), and 1.2% acetic 
acid (Kanto Chemical, Tokyo, Japan)]. After incubation at room 
temperature for 20 min, Ehrlich’s solution [1 mol/l 
4-dimethylaminobenzaldehyde (Sigma-Aldrich), 18% perchloric acid 
16 
 
(Sigma-Aldrich), and 60% n-propanol] was added, and the samples were 
incubated at 65°C for 40 min. Absorbance was measured at 560 nm 
(SpectraMax M5e, SoftMax Pro ver. 5.4.1, Molecular Devices, Sunnyvale, 
CA, USA). The concentration of hydroxyproline was estimated by a 
standard curve using a pure solution of l-hydroxyproline (Wako Pure 
Chemical Industries). Final results were expressed as hydroxyproline per 
mg protein. The kidney protein concentration was determined using the 
BCA protein assay (Pierce, Thermo Scientific, Waltham, MA, USA) with 
bovine serum albumin as a standard. 
 
Quantitative real-time PCR analyses 
Total RNA was extracted from the kidney using TRIzol Reagent 
(Invitrogen Life Technologies) and purified according to the 
manufacturer’s protocol of RNeasy Mini Kit (74106, QIAGEN, Venlo, 
Netherlands). Furthermore, the total RNA concentration was determined 
using NanoDrop 1000 Spectrophotometer (Thermo Scientific). cDNA was 
synthesized from 1g of total RNA with SuperScript VILO Master Mix 
(11755250, Invitrogen, Life Technologies) using the iCycler Thermal 
Cycler (Bio-Rad, Hercules, CA, USA). Quantitative real-time PCR was 
performed in 7500 Fast Real-Time PCR System (Applied Biosystems, Life 
Technologies) using the TaqMan technology. Data was analysed using the 
standard curve method. The results of each gene were normalized to that of 
18SrRNA as an internal control. The following TaqMan Gene Expression 
Assay reagents (Applied Biosystems, Life Technologies) were used 
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(TGF-1, Mm00441724_m1; -SMA, Mm01546133_m1; collagen 1a2, 
Mm00483888_m1; 18SrRNA, 4308329).  
 
Western blotting analyses 
Kidney tissues were homogenized in a lysis buffer containing 50 mmol/l 
Tris-HCl pH 8.0 (Nacalai Tesque, Kyoto, Japan), 150 mmol/l NaCl (Wako 
Pure Chemical Industries), 0.5% sodium deoxycholate (Wako Pure 
Chemical Industries), 0.1% sodium dodecyl sulfate (Bio-Rad), 1% Triton 
X-100 (Sigma-Aldrich), 1x protease inhibitors (complete, 11697498001, 
Roche, Basel, Switzerland), and 1x phosphatase inhibitors (P2850, 
Sigma-Aldrich). Following centrifugation at 15,000 x g for 20 min at 4°C 
(CF-15R, Hitachi Koki, Tokyo, Japan), the supernatant was collected as the 
lysate. The lysates were denatured for 5 min by boiling. Protein 
concentration was determined using the BCA protein assay (Pierce, Thermo 
Scientific) with bovine serum albumin as a standard. Equal amounts of 
lysates were separated on a 4%–15% TGX Precast Gel (Bio-Rad), and 
transferred to a polyvinyliden difluoride membrane using the Trans-Blot 
Turbo Transfer System (Bio-Rad). The blots were blocked in Starting 
Block T20 (PBS) Blocking Buffer (Pierce, Thermo Scientific) at room 
temperature for 1 h. They were subsequently incubated overnight at 4°C 
with the primary antibodies [anti-ROCK1 rabbit polyclonal antibody 
(1:200, H-85, sc-5560, Santa Cruz Biotechnology, Santa Cruz, CA, USA), 
anti--actin mouse monoclonal antibody (1:1000, C4, sc-47778, Santa Cruz 
Biotechnology), anti-ROCK2 mouse monoclonal antibody (1:5000, 610624, 
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Transduction Laboratories, BD, Franklin Lakes, NJ, USA), anti-MYPT-1 
rabbit polyclonal antibody (1:1000, 2634, Cell Signaling Technology, 
Danvers, MA, USA), and anti-phospho-MYPT-1 (Thr853) rabbit 
polyclonal antibody (1:1000, 4563, Cell Signaling Technology)] in Can Get 
Signal solution (Toyobo, Osaka, Japan). They were then incubated with 
secondary antibodies [ECL Anti-rabbit IgG, Horseradish 
Peroxidase-Linked Species-Specific Whole Antibody from donkey (1:5000, 
NA934, GE healthcare, Buckinghamshire, UK) and ECL Anti-Mouse IgG, 
Horseradish Peroxidase-Linked Species-Specific Whole Antibody from 
sheep (1:5000, NA931, GE healthcare)] and developed using enhanced 
chemiluminescence methods (54-71-00, LumiGLO Reserve 
Chemiluminescent Substrate Kit, KPL, Gaithersburg, MD, USA). The 
signal intensities of specific bands were detected using LAS-3000 
Luminescent Image Analyzer (Fujifilm, Tokyo, Japan) and analyzed by 
Multi Gauge program (ver. 3.0, Fujifilm). For quantification, the signal 
intensities were normalized to -actin loaded in each well. 
 
Statistical analyses 
All data are expressed as means ± standard error mean. Parameters 
between the sham- and UUO-operated mice or between the WT and 
ROCK2 HKO mice were compared by Student’s t-test. P < 0.05 was 
considered as statistically significant. 
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Results 
 
Hydroxyproline content in the UUO kidney 
To assess renal interstitial fibrosis, I evaluated the collagen accumulation 
in UUO kidneys. Total kidney collagen deposition was determined by 
measuring the hydroxyproline content, which significantly increased in the 
UUO-operated kidney, compared to that of the sham-operated kidney. After 
the 3 days of UUO, the hydroxyproline content continued to increase (data 
not shown). At days 7 and 14 after UUO, I compared the WT and HKO 
mice. Moreover, the hydroxyproline content increased in the 
UUO-operated kidney of both the WT (2.4- and 4.4-fold at days 7 and 14 
after UUO, respectively) and HKO mice (2.6- and 4.1-fold at days 7 and 14 
after UUO, respectively, Fig. 5). There was no significant difference. 
 
Expression of collagen I, -SMA, and TGF-1 mRNA in the UUO 
kidneys 
I measured the fibrosis-related gene expression to examine the effect of 
partial ROCK2 deletion. The levels of collagen I, -SMA, and TGF-1 
mRNA in the UUO-operated kidney of the WT mice markedly increased 
compared to those in the sham-operated kidney (collagen I, 11.0- and 
11.8-fold; -SMA, 5.1- and 6.9-fold; TGF-1, 7.9- and 7.9-fold at days 7 
and 14 after UUO, respectively). In contrast, the expression level of 
-SMA mRNA markedly ameliorated in the HKO mice at day 7 after UUO 
to 78% of the level noted in the WT mice (Fig. 6B). At day 14 after UUO, 
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the expression level of -SMA mRNA in the HKO mice was not 
statistically significant; however, it was suppressed to 81% of that in the 
WT mice. Moreover, collagen I and TGF-1 mRNA expression levels 
increased in the UUO-operated kidney of HKO mice (collagen I, 9.9- and 
10.8-fold; TGF-1, 6.9- and 7.4-fold at days 7 and 14 after UUO, 
respectively); their expression levels were almost the same compared with 
those in the WT mice (Fig. 6A, C). 
 
ROCK activity in the UUO kidneys 
To confirm the difference in the ROCK activity between the WT and 
HKO mice, I measured the phosphorylation of MYPT-1, a target protein of 
ROCK in the UUO-operated kidney. The phosphorylated MYPT-1 was 
detected in the UUO-operated kidney of both the WT and HKO mice in a 
similar manner (Fig. 7), indicating that the ROCK activity did not change 
the partial ROCK2 deletion. In the normal kidney, ROCK2 protein 
expression level in the HKO mice was a half of that in the WT mice (Fig. 
8). However, the expression level of ROCK1 protein did not change 
between the WT and HKO mice in the kidney; the expression ratio of 
ROCK1 and ROCK2 also did not change in the UUO-operated kidney 
(data not shown). 
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Discussion 
 
In the present study, I investigated the effects of the partial deletion of 
ROCK2 protein on fibrosis-related genes and renal interstitial fibrosis in 
mice UUO model. In the WT mice, the hydroxyproline content and 
expression of collagen I mRNA in the UUO-operated kidney significantly 
increased at days 7 and 14 after ureteral occlusion. The fibrotic parameters 
in the UUO kidney of ROCK2 HKO mice also increased. However, there 
was no statistical difference between the WT and ROCK2 HKO mice on 
the increment of these fibrotic parameters in the UUO-operated kidney, 
suggesting that the partial deletion of ROCK2 protein does not influence 
renal interstitial fibrosis induced by UUO. It has been reported in normal 
mice that Y27632, a non-selective ROCK1/2 inhibitor, suppresses the 
collagen I mRNA expression and collagen deposition in damaged kidney at 
days 4 and 10 after UUO (27). In rat UUO model, fasudil ameliorated the 
collagen deposition in damaged kidney at day 16 after UUO (28). These 
results suggest that the pharmacological inhibition of ROCK can prevent 
the development of UUO-induced renal interstitial fibrosis. In contrast, 
other investigators demonstrated that in ROCK1 KO mice, complete 
ROCK1 deletion did not affect collagen accumulation and collagen I 
mRNA expression in the UUO kidney at days 5 and 10 after UUO. This 
suggests that ROCK2, but not ROCK1, is involved in renal interstitial 
fibrosis in UUO (30). However, in this study, partial ROCK2 deletion 
indicated a non-significant reduction in renal interstitial fibrosis. Thus, it is 
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likely that the effect of the pharmacological inhibition of ROCK is 
inconsistent with that of the deletion of ROCK protein on the development 
of renal interstitial fibrosis after UUO. 
It is evident that TGF-1 signals and the Rho/ROCK pathway are closely 
associated with renal interstitial fibrosis by UUO (40). Y27632 is reported 
to suppress the augmentation of TGF-β1 mRNA expression in UUO mice 
(27). However, in ROCK1 KO mice, TGF-1 expression was significantly 
enhanced in the damaged kidney after UUO compared with the WT mice 
because the absence of ROCK1 may not be able to suppress TGF-1 
expression to protect renal fibrosis (30). Therefore, ROCK2 was considered 
to play an important role in TGF-1 signaling in renal interstitial fibrosis 
after UUO. In the present study, partial ROCK2 deletion did not suppress 
TGF-1 and ROCK1 mRNA expression, and ROCK activity remained 
unaffected in the UUO-operated kidney. These results suggest that the 
response to partial ROCK2 deletion is distinct from that to pharmacological 
ROCK inhibition. 
In renal interstitial fibrosis, the transformation to myofibroblasts, which 
are considered to be the dominant collagen producing cells, is a crucial step 
toward collagen synthesis and deposition. In kidney fibrosis, the resident 
fibroblast, epithelial, endothelial, and bone marrow-derived cells can 
acquire the myofibroblast phenotype and express the characteristic proteins, 
such as -SMA. Further, the ROCK signaling pathway is reported to play 
an important role in cell transformation to activated myofibroblasts (41, 42). 
In the present study, the level of -SMA expression markedly decreased in 
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the UUO kidney of ROCK2 HKO mice compared with that of the WT mice. 
In ROCK1 KO mice, the augmentation of -SMA mRNA and protein 
caused by UUO were not decreased (30). Thus, it is likely that ROCK2 
may be implicated in UUO-induced transformation via any signal cascade 
independent of TGF-1. In addition, I found in mice UUO model that the 
effect of ROCK2 HKO is inconsistent with that of the pharmacological 
inhibition of ROCK. With respect to the inconsistence, ROCK inhibitors 
are considered to be poor in isoform selectivity and other target specificity. 
Y-27632 and fasudil equivalently inhibit both ROCK1 and ROCK2 
activity; fasudil also inhibits PKN, PKC, myosin light chain kinase, and 
MEK1. It must be considered that the partial deletion of ROCK2 may be 
insufficient in suppressing UUO-induced fibrotic responses. Moreover, it is 
possible that the results depend on experimental procedures and 
pathophysiological conditions in the UUO model. In order to solve these 
problems, further studies are required using a kidney-specific ROCK1 or 
ROCK2 deletion and using more specific inhibitors for ROCK1 or ROCK2. 
In conclusion, using ROCK2 HKO mice, I demonstrated that the partial 
deletion of ROCK2 as well as ROCK1 inhibition is insufficient in 
effectively preventing renal interstitial fibrosis. 
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Figures 
 
 
 
 
 
Fig. 5. The hydroxyproline content in the kidney of WT and HKO 
mice at days 7 and 14 after UUO 
The hydroxyproline content in the kidney of the UUO operated mice was 
compared with that of the sham-operated mice at days 7 and 14 after UUO. 
The symbols are WT mice (open bar) and HKO mice (solid bar). Results 
are expressed as mean ± SEM (n = 5–10). *** P < 0.001 compared to the 
sham group.  
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Fig. 6. Collagen I, -SMA, and TGF-1 mRNA expression in the 
kidney of WT and HKO mice at days 7 and 14 after UUO 
Collagen I (A), -SMA (B), and TGF-1(C) mRNA expression in the 
UUO-operated mice were compared with that in the sham-operated mice at 
days 7 and 14 after UUO. The symbols are WT mice (open bar) and HKO 
mice (solid bar). Results are expressed as mean ± SEM (n = 5–10). ***P < 
0.001 compared to sham group and ##P < 0.01 compared to WT mice at 
the same time point. 
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Fig. 7. The ROCK activity of WT and HKO mice in the kidney 
(A) Representative western blotting photographs demonstrate the levels of 
MYPT-1 (upper panel) and phospho-MYPT-1 (middle panel) proteins in 
the kidney of WT and HKO mice at day 7 after UUO. The same blot was 
detected with -actin (lower panel) to confirm equal loading. (B) 
Quantitative analysis shows the relative abundance of the 
phospho-MYPT-1/MYPT-1 ratio after normalization with -actin. Results 
are expressed as mean ± SEM (n = 3–5). The symbols are WT mice (open 
bar) and HKO mice (solid bar). 
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Fig. 8. ROCK1 and ROCK2 proteins expression of WT and HKO mice 
in the normal kidney 
(A) Representative western blotting photographs demonstrate the levels of 
ROCK1 (upper panel) and ROCK2 (middle panel) proteins in the normal 
kidney of WT and HKO mice. The same blot was detected with -actin 
(lower panel) to confirm equal loading. (B) Quantitative analysis shows the 
relative abundance of the ROCK1 or ROCK2 protein after normalization 
with -actin. Results are expressed as mean ± SEM (n = 7). The symbols 
are WT mice (open bar) and HKO mice (solid bar). ###P < 0.001 compared 
to WT mice. 
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Chapter III 
The inhibitory effects of fasudil on renal interstitial fibrosis induced by 
unilateral ureteral obstruction 
 
Summary 
 
Several studies have reported that ROCK inhibitors attenuate renal fibrosis. 
However, the mechanism of this process is still incompletely understood. I 
assessed the inhibitory effect of fasudil, a ROCK inhibitor, in vivo and in 
vitro to elucidate the mechanisms underlying renal interstitial fibrosis. In 
mice with UUO, the collagen accumulation, fibrosis-related gene 
expression, and hydroxyproline content in the kidney increased 3, 7, and 14 
days after UUO. Fasudil attenuated the histological changes and the 
production of collagen and ECM in the UUO kidney. The expression of 
-SMA, TGF--Smad signaling pathway, and macrophage infiltration were 
suppressed by fasudil in the kidneys of the UUO mice. I also evaluated the 
role of intrinsic renal cells and infiltrated macrophages using NRK-52E, 
NRK-49F, and RAW264.7 cells. The mRNA and protein expression of 
collagen I and -SMA increased in NRK-52E and NRK-49F cells 
stimulated by TGF-1. Hydroxyfasudil, a bioactive metabolite of fasudil, 
attenuated the increase in -SMA mRNA and protein expression levels in 
both cell types. However, the reduction in collagen I mRNA levels was 
observed in NRK-49F cells alone. Hydroxyfasudil decreased MCP-1 
mRNA expression induced by TGF-1 in NRK-52E but not in NRK-49F 
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cells. In RAW264.7 cells, MCP-1, IL-1, IL-6, and TNF mRNA 
expression, significantly elevated by lipopolysaccharide (LPS) stimulation, 
was not suppressed by hydroxyfasudil. These data suggested that the 
inhibition of ROCK suppressed renal interstitial fibrosis via TGF--Smad 
signaling pathway and decreased the infiltration of macrophages to the 
injured kidney. However, the cytokine/chemokine expression in 
macrophages was unaffected. It is likely that ROCK contributes to the 
activation of renal intrinsic cells and migration of extra-renal cells in the 
progression of renal interstitial fibrosis. 
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Introduction 
 
Fasudil and Y27632, the non-selective ROCK1/2 inhibitor, have been 
used to evaluate the role of ROCK in several animal disease models. In the 
rat heart ischemia-reperfusion (IR) model, fasudil reduces the infarct size 
by attenuating endoplasmic reticulum stress and modulating SERCA 
activity (43). Similarly, in rat kidney IR model, fasudil suppresses the renal 
injury and improves kidney function (44). Furthermore, fasudil shows the 
renoprotective effects such as improving albuminuria and mesangial matrix 
expansion. It also suppresses renal injury by downregulation of 
hypoxia-inducible factor 1 in diabetic nephropathy model (45). Some in 
vitro studies, using mesangial, tubular epithelial, or kidney fibroblast cells 
(46-48), have reported that Y27632 inhibits cell hypertrophy, expression of 
-SMA, and collagen expression induced by aldosterone or TGF-1. These 
reports have suggested that ROCK inhibitors use a variety of functional 
mechanisms and are effective in a wide range of diseases. 
Renal tubulointerstitial fibrosis is a common pathway in progressive renal 
diseases. The UUO model is widely used in the studies of progressive 
interstitial fibrosis that is independent of hypertension or systemic immune 
disease. After UUO, the obstructed kidney exhibits a substantial 
macrophage influx into the interstitium and develops tubulointerstitial 
fibrosis. Fasudil and Y27632 have been reported to prevent 
tubulointerstitial fibrosis in the UUO model by inhibiting the expression of 
collagen, TGF-1, and -SMA mRNAs (27-29). However, the details of 
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the mechanism are still incompletely understood. In this study, I 
investigated the effect of a ROCK inhibitor on renal interstitial fibrosis, 
renal intrinsic cells, and the cells infiltrating the kidney. 
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Materials and methods 
All animal experiments were conducted according to the Experimental 
Animal Care and Use Committee, Mitsubishi Tanabe Pharma Corporation, 
that was regulated by Management and Ethics of Animal (Law No. 105, 
1973, Japan). In addition, this study was performed according to the 
reliability standards (Article 43 of the Pharmaceutical Affairs Law 
Enforcement Regulations, Japan). 
 
Animals 
Male C57BL/6J mice were purchased from Charles River Japan; they 
were maintained at room temperature on a 12-h light/dark cycle and 
allowed ad libitum access to standard laboratory chow (CRF-1) and tap 
water. The animals were kept at the departmental animal care facility of 
Mitsubishi Tanabe Pharma Corporation in accordance with the relevant 
protocols.  
 
Unilateral ureteral obstruction model 
Mice were anesthetized with sevofrane and subjected to a left flank 
incision. UUO was performed by a complete ligation of the left ureter at 
the ureteropelvic junction with a 4-0 silk suture. The sham-operated mice 
had their ureter exposed without ligation. All mice were used in the 
experiments at 9 weeks of age after 1 week of the acclimation period. 
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UUO-operated mice were randomly divided into the following groups: 
sham, UUO-control, and UUO-fasudil (1 g/l, Mitsubishi Tanabe Pharma, 
Osaka, Japan). Fasudil was given in drinking water 2 days before UUO 
operation until the day of sacrifice. The mice were euthanized under 
anesthesia with sevofrane on days 3, 7, and 14 after operation. Kidneys 
were then removed and divided into several parts (for RNA, 
hydroxyproline, immunohistochemistry assays, and protein sections). 
 
Cell culture 
The rat kidney tubular epithelial cell line (NRK-52E), fibroblast cell line 
(NRK-49F), and the mouse macrophage cell line (RAW264.7), obtained 
from the American Type Culture Collection (ATCC, Manassas, VA, USA), 
were cultured in low glucose (5 mmol/l) Dulbecco’s modified Eagle’s 
medium (D6046, Sigma-Aldrich) supplemented with 10% fetal bovine 
serum (S1820, Biowest, Nuaille, France) at 37°C under 5% CO2 
atmosphere. For experimental treatments, serum was reduced to 1% for 20 
h and recombinant human TGF-1 (10 ng/ml, 100-21C, Peprotech, Rocky 
Hill, NJ, USA) or LPS (500 ng/ml, L4391, Sigma-Aldrich) was added for 
24 h. To investigate the role of ROCK under these conditions, 10 or 30 
mol/l of hydroxyfasudil (Mitsubishi Tanabe Pharma), a bioactive 
metabolite of fasudil, was added to the cells 1 h before TGF-1 or LPS 
stimulation. 
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Histology and Immunohistochemistry 
The kidneys were removed and immediately fixed in 10% formaldehyde 
neutral buffer solution (Nacalai Tesque). The formalin-fixed kidneys were 
embedded in paraffin. Paraffin sections were stained with hematoxylin 
(115938, Merck, Darmstadt, Germany) and eosin (115935, Merck), and 
Sirius Red (365548, Sigma-Aldrich)/Fast Green (069-00032, Wako Pure 
Chemical Industries, Osaka, Japan). Immunohistochemistry was performed 
as described previously (49). Briefly, kidney paraffin sections were 
deparaffinized. Sections were pretreated with 3% hydrogen peroxide. The 
sections were incubated overnight at 4°C with anti--SMA mouse 
monoclonal antibody (1:500, A2547, Sigma-Aldrich) or anti-F4/80 rat 
monoclonal antibody (1:100, MCA497G, AbD Serotec, Kidlington, UK) 
followed by the incubation with HRP-conjugated anti-mouse IgG 
secondary antibody (414321, Histofine Mouse Stain kit, Nichirei 
Biosciences, Tokyo, Japan) and HRP-conjugated anti-rat IgG secondary 
antibody (414311, Histofine Simple Stain Mouse MAX PO Rat, Nichirei 
Biosciences), respectively. The sections were colorized with 
3,3′-diaminobenzidine (Nacalai Tesque) and counterstained with 
hematoxylin (30002, Muto Pure Chemicals, Tokyo, Japan). The sections 
were photographed with a DP73 digital camera system (Olympus, Tokyo, 
Japan) equipped with cellSens software (Olympus) and a BX51 microscope 
(Olympus). For image analysis, whole-slide digital images of the sections 
were obtained with Aperio Scan Scope XT (Leica Microsystems, Wetzlar, 
Germany). Sirius Red-, -SMA-, and F4/80-positive areas were determined 
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using Image-Pro Plus software (Media Cybernetics, Bethesda, MD, USA) 
as described previously (49). 
 
Determination of kidney hydroxyproline content 
The collagen content in the kidney was determined using hydroxyproline 
assay (modified as previously described) (38, 39). In brief, the kidneys 
were homogenized in phosphate-buffered saline (700 ml/100 mg kidney 
weight), completely hydrolyzed in 6 mol/l HCl at 120°C for 6 h, and 
filtered through a 0.45-m Millex-HV filter. The samples were dried by 
vacuum centrifugation using EZ-2 plus for 16 h. Dried samples were 
solubilized in distilled water. The samples were oxidized using chloramine 
T solution (1.4% sodium p-toluenesulfonchloramide trihydrate  and 10% 
n-propanol  in citric acid buffer, which was consisted of 0.26 mol/l citric 
acid, 0.88 mol/l sodium acetate trihydrate, 0.85 mol/l sodium hydroxide, 
and 1.2% acetic acid). After incubation at room temperature for 20 min, 
Ehrlich’s solution (1 mol/l 4-dimethylaminobenzaldehyde, 18% perchloric 
acid, and 60% n-propanol) was added, and the samples were incubated at 
65°C for 40 min. Absorbance was measured at 560 nm. The concentration 
of hydroxyproline was estimated from a standard curve prepared using a 
pure solution of l-hydroxyproline. Final results were expressed as 
hydroxyproline per mg of protein. The kidney protein concentration was 
determined using the BCA protein assay with bovine serum albumin as a 
standard. 
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Quantitative real-time PCR analyses 
Total RNA was extracted from the kidney and cultured cells using TRIzol 
Reagent and purified according to the RNeasy Mini Kit manufacturer’s 
protocol. The total RNA concentration was determined using NanoDrop 
1000 Spectrophotometer. cDNA was synthesized from 1g of total RNA 
with SuperScript VILO Master Mix using the iCycler Thermal Cycler. 
Quantitative real-time PCR was performed in 7500 Fast Real-Time PCR 
System using the TaqMan technology. Data was analysed using the 
standard curve method. The results for each gene were normalized to 
18SrRNA (an internal control). The following TaqMan Gene Expression 
Assay reagents were used: ROCK1 (Mm00485745_m1), ROCK2 
(Mm00485761_m1), TGF-1 (Mm00441724_m1), -SMA 
(Mm01546133_m1, Rn01759928_g1), collagen 1a2 (Mm00483888_m1, 
Rn01526721_m1), collagen 3a1 (Mm01254477_m1), fibronectin 
(Mm01256744_m1), MCP-1 (Mm00441242_m1, Rn00580555_m1), F4/80 
(Mm00802529_m1), IL-1 (Mm00434228_m1), TNF 
(Mm00443258_m1), IL-6 (Mm00446190_m1), and 18SrRNA (4308329). 
 
Western blotting analyses 
Kidney tissues and cultured cells were homogenized in a lysis buffer 
containing 50 mmol/l Tris-HCl pH 8.0, 150 mmol/l NaCl, 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulfate, 1% Triton X-100, 1x protease 
inhibitors, and 1x phosphatase inhibitors. Following centrifugation at 
15,000 x g for 20 min at 4°C, the supernatant was collected as the lysate. 
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The lysates were denatured for 5 min by boiling. Protein concentration was 
determined using the BCA protein assay with bovine serum albumin as a 
standard. Equal amounts of lysates were separated on a 4%–15% TGX 
Precast Gel, and transferred to a polyvinylidene difluoride membrane  
using the Trans-Blot Turbo Transfer System. The blots were blocked in 
Starting Block T20 (PBS) Blocking Buffer at room temperature for 1 h. 
They were subsequently incubated overnight at 4°C with the primary 
antibodies [anti-phospho-MYPT-1 (Thr850) rabbit polyclonal antibody 
(1:1000, 36-003, Merck Millipore), anti-GAPDH mouse monoclonal 
antibody (1:500, MAB374, Merck Millipore), anti-collagen type I rabbit 
polyclonal antibody (1:2000, ABT123, Merck Millipore), 
anti-phospho-Smad3 (Ser423 + Ser425) rabbit polyclonal antibody (1:2000, 
ab51451, Abcam, Cambridgeshire, UK), anti--SMA rabbit polyclonal 
antibody (1:500, 14395-1-AP, Proteintech, Chicago, IL, USA)] in Can Get 
Signal solution. They were then incubated with secondary antibodies [ECL 
Anti-rabbit IgG, Horseradish Peroxidase-Linked Species-Specific Whole 
Antibody from donkey (1:5000) and ECL Anti-Mouse IgG, Horseradish 
Peroxidase-Linked Species-Specific Whole Antibody from sheep (1:5000)] 
and developed using enhanced chemiluminescence methods. The signal 
intensities of specific bands were detected using LAS-3000 Luminescent 
Image Analyzer and analyzed by Multi Gauge program (ver. 3.0). For 
quantification, the signal intensities were normalized to GAPDH loaded in 
each well. 
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Statistical analyses 
All data are expressed as means ± standard error. The comparisons 
between the sham- and UUO-operated control mice, the control and 
fasudil-treated mice, the non-stimulated cells and stimulated cells, and 
between the stimulated cells and hydroxyfasudil-treated cells were 
conducted using Student’s t-test. P < 0.05 was considered statistically 
significant. 
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Results 
 
Effect of fasudil on renal histological changes 
The kidneys of the UUO mice progressively developed renal parenchymal 
thinning accompanied by severe tubulointerstitial damage including tubular 
atrophy/dilation, tubular regeneration, and interstitial infiltration (Fig. 9) as 
reported previously (4, 5). Fasudil administration had a little effect on these 
changes. 
 
Effect of fasudil on the interstitial fibrosis 
To determine the effect of fasudil on interstitial fibrosis in the kidneys of 
the UUO mice, we stained the collagen in the interstitium with Sirius Red 
and measured the hydroxyproline content and extracellular matrix mRNA 
expression. In the obstructed kidney, the Sirius Red-positive areas in the 
renal interstitium increased progressively in comparison with those in the 
sham-operated kidney during the 14-day period (2.7-, 3.5-, and 6.0-fold 
increase at days 3, 7, and 14 after UUO, respectively, Fig. 10A and 10B). 
The content of hydroxyproline was also augmented (1.9-, 3.2-, and 6.6-fold 
at days 3, 7, and 14 after UUO, respectively, Fig. 10C). Furthermore, the 
expression levels of mRNAs for collagen I, III, and fibronectin were higher 
in the kidneys of the UUO mice than in the sham group (collagen I, 7.4-, 
14.3-, and 21.3-fold; collagen III, 11.9-, 20.9-, and 35.2-fold; fibronectin, 
6.6-, 17.4-, and 31.0-fold at days 3, 7, and 14 after UUO, respectively, Fig. 
11A–11C). On day 14 after UUO, administration of fasudil significantly 
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suppressed these augmented levels. On day 7 after UUO, the Sirius 
Red-positive areas and fibronectin mRNA expression did not significantly 
decrease. However, the expression of collagen I and III mRNA and 
hydroxyproline content in the injured kidney were markedly suppressed by 
fasudil administration. These results suggest that fasudil ameliorates the 
interstitial fibrosis. 
 
Effect of fasudil on the -SMA expression 
I next examined the effect of fasudil on interstitial myofibroblasts 
(characterized by the expression of -SMA). Immunohistochemical 
staining showed larger numbers of -SMA-positive cells in the interstitium 
of the UUO mice than in the sham-operated mice (12.3-, 16.4-, and 7.2-fold 
increase at days 3, 7, and 14 after UUO, respectively, Fig. 12A and 12B). 
Similarly, the expression of -SMA mRNA increased in the UUO mice 
(5.9-, 5.6-, and 10.5-fold at days 3, 7, and 14 after UUO, respectively, Fig. 
12C). Both immunohistochemical staining and mRNA expression analysis 
(showing reduction of 65% and 28%, respectively) on day 7 after UUO 
demonstrated that fasudil administration markedly inhibited the increase in 
-SMA expression in the interstitium. Furthermore, the mRNA expression 
was significantly suppressed on day 14 after UUO (reduced by 17%). 
These results indicate that fasudil administration inhibits the transformation 
of renal cells or extra-renal cells to myofibroblasts or the proliferation of 
myofibroblasts. 
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Effect of fasudil on the macrophage infiltration 
ROCK inhibitors have the ability to suppress the cell migration. I 
examined the F4/80-positive cells and F4/80 mRNA expression to assess 
the effect of fasudil on the macrophage infiltration to the kidney. The 
immunohistochemical staining detected the F4/80-positive cells in the 
interstitium of the injured kidney; their number in UUO mice progressively 
increased in comparison with the sham group (3.0-, 22.7-, and 30.2-fold at 
days 3, 7, and 14 after UUO, respectively, Fig. 13A and 13B). Fasudil 
administration clearly inhibited the macrophage infiltration into the injured 
kidney (the numbers reduced by 55% and 28% at days 7 and 14 after UUO, 
respectively). Similarly, the F4/80 mRNA expression was augmented (2.0-, 
5.5-, and 10.0-fold at days 3, 7, and 14 after UUO, respectively, Fig. 13C); 
this increase was significantly inhibited by administration of fasudil on day 
14 after UUO. However, the augmented expression of MCP-1 mRNA was 
not affected by fasudil (Fig. 13D). These results suggest that fasudil 
inhibits the migration of macrophages to the injured kidney but does not 
affect the MCP-1 expression. 
 
Effect of fasudil on the ROCK activity 
To confirm the effect of fasudil on the ROCK activity, I measured the 
phosphorylation of MYPT-1 in the kidney. The level of phosphorylation 
increased in the obstructed kidney in comparison with sham group (1.4-, 
1.4-, and 1.7-fold at days 3, 7, and 14 after UUO, respectively, Fig. 14A). 
Fasudil treatment did not have a statistically significant effect on the 
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phosphorylation levels; however, ROCK activity was suppressed to the 
basal level. The expressions of ROCK1 and ROCK2 mRNA increased in 
UUO mice, but fasudil did not affect the expressions of these mRNA (Fig. 
14B and 14C). 
 
Effect of fasudil on the TGF--Smad signaling pathway 
It is known that TGF--Smad signaling pathway is activated in the kidney 
of the UUO mice. To examine the effect of fasudil on this pathway, I 
measured the expression of TGF-1 mRNA and the level of phosphorylated 
Smad3. The expression of TGF-1 mRNA increased in UUO kidneys (3.0-, 
6.0-, and 7.2-fold at days 3, 7, and 14 after UUO, respectively, Fig. 15A) in 
comparison with that in the sham-group kidneys. Fasudil administration 
significantly suppressed this increase in the obstructed kidney (by 18%) on 
day 14. In the kidneys of the UUO mice, the level of phosphorylated 
Smad3 progressively increased in comparison with that in the 
sham-operated kidneys (3.8-, 5.3-, and 13.1-fold at days 3, 7, and 14 after 
UUO, respectively, Fig. 15B). This increase was markedly reduced by 
fasudil (by 29% on day 3 and 37% on day 7 after UUO). These results 
demonstrated that fasudil blocked the TGF--Smad signaling pathway 
involved in the interstitial fibrosis. 
 
Effect of hydroxyfasudil on the NRK-52E and NRK-49F cells 
These results from animal experiments indicated that fasudil attenuated 
the renal interstitial fibrosis and migration of macrophages to the kidney 
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interstitium. Using NRK-52E and NRK-49F cells, I also determined the 
effect of fasudil on the intrinsic renal cells. In the kidney of UUO mice, 
TGF-1 is recognized as a vital mediator in renal fibrosis. In NRK-52E and 
NRK-49F cells, TGF-1 induced the expressions of -SMA and collagen I 
mRNA and their proteins (Fig. 16A and 16B). Hydroxyfasudil, a bioactive 
metabolite of fasudil, particularly decreased -SMA mRNA expression 
induced by TGF-1 in both cell types. Furthermore, in NRK-49F cells, 
-SMA protein production was markedly reduced by 30 mol/l 
hydroxyfasudil treatment. However, in NRK-52E cells, the augmentation of 
-SMA protein production did not found in this condition. In NRK-49F 
cells, the increased expression of collagen I mRNA was significantly 
attenuated by 30 mol/l hydroxyfasudil treatment; however, the protein 
production was unaffected. In contrast, in NRK-52E cells, hydroxyfasudil 
did not affect the levels of collagen I mRNA or its protein. In the kidneys of 
UUO mice, MCP-1 mRNA expression level increased in comparison with 
the level in the sham-operated kidneys. These increased levels were 
unaffected by fasudil (Fig. 13D). The expression of MCP-1 mRNA was 
stimulated by TGF-1 in both NRK-52E and NRK-49F cells. Pretreatment 
with hydroxyfasudil clearly suppressed the induction of MCP-1 mRNA 
expression in NRK-52E cells but had no effect in NRK-49F cells (Fig. 
16C). 
 
Effect of hydroxyfasudil on RAW264.7 cell 
The migration of macrophages to the kidney interstitium has been 
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observed in the UUO model. At an early stage of the UUO, M1 
macrophages, the classically activated macrophages, infiltrate the kidney 
and are involved in the inflammation and phagocytosis (50). I used 
RAW264.7 cells, stimulated by LPS, as M1 subtype cells. In these 
activated RAW264.7 cells, the expression of MCP-1, IL-1, IL-6, and 
TNF mRNAs was dramatically augmented (Fig. 17A-17D). 
Hydroxyfasudil did not affect the expression levels of these mRNA. 
  
45 
 
Discussion 
 
The UUO model is useful for examination of the mechanisms of 
tubulointerstitial fibrosis in vivo. The interstitial inflammation occurs 
rapidly (2–3 days) and the subsequent histological changes such as tubular 
dilation, tubular atrophy, and fibrosis are observed soon after (~7 days). 
These common alterations are found in several tubulointerstitial diseases 
(2-7, 51). A study of the ROCK1 KO mice (30) has reported no inhibition 
of the interstitial fibrosis, although pharmacological inhibitors, fasudil and 
Y27632, inhibit the fibrosis in UUO model (27-29). To clarify the 
mechanisms of suppression of the interstitial fibrosis, I investigated the 
inhibition of ROCK using the pharmacological ROCK inhibitor, fasudil. 
I demonstrated that fasudil reduced the renal interstitial fibrosis and 
attenuated the histological changes in the UUO mice. The results of 
immunohistochemical staining and mRNA expression analysis showed that 
fasudil markedly suppressed -SMA expression in the injured kidney. In 
the process of the kidney fibrosis, the number of myofibroblasts producing 
extracellular matrix proteins increases in the tubular interstitium. These 
cells express a distinctive protein, -SMA. Until recently, tubular epithelial 
cells have been considered the main source of the interstitial 
myofibroblasts. However, many studies have reported that the 
transformation to myofibroblasts occurs in various cells such as epithelial 
cells, endothelial cells, bone marrow-derived cells, resident fibroblasts, and 
pericytes (52-56). In this study, I used a tubular epithelial cell line, 
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NRK-52E, and a fibroblast cell line, NRK-49F, to examine the 
transformation to myofibroblasts and analyze the fibrosis-related gene 
expressions. In NRK-49F cells, hydroxyfasudil attenuated the -SMA 
mRNA and protein expression stimulated by TGF-1. I observed that the 
upregulated collagen I mRNA expression was suppressed by high 
dose-hydroxyfasudil in NRK-49F cells only. These results suggest that 
fasudil inhibits TGF-1-induced transformation and collagen synthesis in 
renal fibroblast cells. In NRK-52E cells, hydroxyfasudil suppressed the 
-SMA mRNA expression induced by TGF-1, but it did not increase the 
-SMA protein levels. It is possible that the basal expression level of 
-SMA is higher than that of other cells under those conditions. Both in 
vitro and in vivo studies have reported that not only TGF-1 but also other 
stimuli such as angiotensin II, aldosterone, and high glucose induce 
collagen production in tubular epithelial cells or fibroblast cells, and ROCK 
inhibitors reduce the collagen production (47, 57, 58). It is possible that 
other stimuli, but not TGF-1, induce the fibrotic responses in NRK-52E 
cells. Thus the inhibition of ROCK suppresses several fibrotic responses in 
tubular epithelial cells and renal fibroblast cells in vivo. 
It has been reported that damaged tubular cells, interstitial myofibroblasts, 
and macrophages produce cytokines, chemokines, and growth factors in the 
UUO kidneys, triggering the accumulation of interstitial macrophages 
(59-61). In this study, fasudil inhibited the infiltration of macrophages into 
the injured kidney. However, the expression of MCP-1 mRNA was not 
affected by fasudil administration. In NRK-49F cells, hydroxyfasudil did 
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not reduce the TGF-1-enhanced MCP-1 mRNA expression. In NRK-52E 
cells, hydroxyfasudil markedly inhibited the increase in MCP-1 mRNA 
expression stimulated by TGF-1. Myofibroblasts in the injured kidney are 
consisted of several different cell types (52-56). It is reported that 
myofibroblasts derived from epithelial cells is small population.  In this 
study, hydroxyfasudil inhibited the MCP-1 mRNA expression in the 
epithelial, NRK-52E cells. Thus it is likely that fasudil is able to suppress 
the MCP-1 production in myofibroblasts that are derived from epithelial 
cells. However, these populations are small in comparison with that of 
other myofibroblast groups; therefore, fasudil may not be able to suppress 
the MCP-1 expression in the overall myofibroblast cell population in the 
injured kidney. Several investigators have also reported that the renal 
interstitial fibrosis can be reduced without inhibition of MCP-1 mRNA 
expression in UUO mice: however, the mechanism has not been clarified 
(62-64). Thus the precise relationship between MCP-1 and ROCK in the 
renal interstitial fibrosis process remains unclear. 
Macrophages are categorized into two functional phenotypes: classically 
activated M1 and alternatively activated M2 (65, 66). In the first stage of 
UUO kidney injury, almost all the infiltrated macrophages show the M1 
phenotype (50). To examine the relationship between macrophages and 
ROCK in the renal interstitial fibrosis, I assessed LPS-induced 
inflammatory response in RAW264.7 cells. LPS stimulation elevated the 
expression of MCP-1, IL-1, IL-6, TNF, and iNOS mRNAs, but it was 
difficult to detect the expression of collagen and TGF-1 mRNA (data not 
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shown). These gene expression patterns are characteristic for the phenotype 
of M1 macrophages. Fasudil treatment did not affect the expression of the 
genes induced by LPS in RAW264.7 cells. These new results suggest that 
ROCK may contribute to the infiltration of monocytes/macrophages into 
the interstitium of the injured kidney rather than affect the inflammatory 
cytokine/chemokine expression. 
Taken together, these data suggest that the inhibition of ROCK suppresses 
the renal interstitial fibrosis via TGF--Smad signaling pathway and the 
infiltration of macrophages to the injured kidney. It is likely that ROCK 
contributes to the activation of the renal intrinsic cells and migration of the 
extra-renal cells in the progression of renal interstitial fibrosis. 
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Figures 
 
 
 
 
 
 
Fig. 9. Histological changes in the kidney 
 The HE-stained sections of the sham- and UUO-operated kidneys. Sham 
(A), UUO-control (B-D), UUO-fasudil (E-G) at days 3, 7, and 14 after 
UUO, respectively (original magnification x10, scale bars: 100 m). 
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Fig. 10. Sirius Red staining and hydroxyproline content in the kidney 
 (A) The Sirius Red-stained sections of the sham- and UUO-operated 
kidneys. Sham (a), UUO-control (b-d), UUO-fasudil (e-g) at days 3, 7, and 
14 after UUO, respectively (original magnification x10, scale bars: 100 
m). (B) The Sirius Red-positive area as percentage of total kidney area. 
(C) The hydroxyproline content in the sham- and UUO-operated kidneys. 
The symbols are: Sham (open bar); UUO-control (Cont, solid bar); 
UUO-fasudil (Fas, hatched bar). Results are expressed as mean ± SEM (n= 
5-7). *** P < 0.001 compared to sham group, # P < 0.05 compared to 
UUO-control mice at the same time point. 
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Fig. 11. The mRNA expression of collagen I, III, and fibronectin in the 
kidney 
 The mRNA expression of collagen I (A), collagen III (B), and fibronectin 
(C) in the sham- and UUO-operated kidneys were showed at days 3, 7, and 
14 after UUO. The symbols are: Sham (open bar); UUO-control (Cont, 
solid bar); UUO-fasudil (Fas, hatched bar). Results are expressed as mean 
± SEM (n= 6-7). *** P < 0.001 compared to sham group, # P < 0.05, ## P 
< 0.01, ### P < 0.001 compared to UUO-control mice at the same time 
point. 
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Fig. 12. The expression of -SMA in the kidney 
 (A) The -SMA immunohistochemistry of the sham- and UUO-operated 
kidneys. Sham (a), UUO-control (b-d), UUO-fasudil (e-g) at days 3, 7, and 
14 after UUO, respectively (original magnification x10, scale bars: 100 
m). (B) The -SMA-positive area as percentage of total kidney area. (C) 
The mRNA expression of -SMA was showed at days 3, 7, and 14 after 
UUO. The symbols are: Sham (open bar); UUO-control (Cont, solid bar); 
UUO-fasudil (Fas, hatches bar). Results are expressed as mean ± SEM (n= 
5-7). **P < 0.01, *** P < 0.001 compared to sham group, # P < 0.05, ## P 
< 0.01 compared to UUO-control mice at the same time point. 
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Fig. 13. The expression of F4/80 and MCP-1 in the kidney 
 (A) The F4/80 immunohistochemistry of the sham- and UUO-operated 
kidneys. Sham (a), UUO-control (b-d), UUO-fasudil (e-g) at days 3, 7, and 
14 after UUO, respectively (original magnification x10, scale bars: 100 
m). (B) The F4/80-positive area as percentage of total kidney area. The 
mRNA expressions of F4/80 (C) and MCP-1 (D) in the sham- and 
UUO-operated kidneys were showed at days 3, 7, and 14 after UUO. The 
symbols are: Sham (open bar); UUO-control (Cont, solid bar); 
UUO-fasudil (Fas, hatched bar). Results are expressed as mean ± SEM (n= 
5-7). ** P < 0.01, *** P < 0.001 compared to sham group, # P < 0.05, ## P 
< 0.01 compared to UUO-control mice at the same time point. 
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Fig. 14. ROCK activity and the mRNA expression of ROCK1 and 
ROCK2 in the kidney 
 (A) Quantitative analysis was showed the relative abundant of the 
phospho-MYPT-1/GAPDH protein levels ratio detected by the western 
blotting. The mRNA expressions of ROCK1 (B) and ROCK2 (C) in the 
sham- and UUO-operated kidneys were showed at days 3, 7, and 14 after 
UUO. The symbols are: Sham (open bar); UUO-control (Cont, solid bar); 
UUO-fasudil (Fas, hatched bar). Results are expressed as mean ± SEM (n= 
6-7). * P < 0.05, ** P < 0.01, *** P < 0.001 compared to sham group. 
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Fig. 15. The expression of TGF-1 and phospho-Smad3 in the kidney 
 (A) The mRNA expression of TGF-1 was showed at days 3, 7, and 14 
after UUO. (B) Quantitative analysis was showed the relative abundant of 
the phospho-Smad3/GAPDH protein levels ratio detected by the western 
blotting. The symbols are: Sham (open bar); UUO-control (Cont, solid bar); 
UUO-fasudil (Fas, hatched bar). Results are expressed as mean ± SEM (n= 
6-7). *** P < 0.001 compared to sham group, # P < 0.05, ## P < 0.01, ### 
P < 0.001 compared to UUO-control mice at the same time point. 
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Fig. 16. The expression of -SMA, collagen I, and MCP-1 in NRK-52E 
and NRK-49F cells 
 (A) The -SMA expression of mRNA and protein were shown in 
NRK-52E (a, b) and NRK-49F (c, d). (B) The collagen I expression of 
mRNA and protein were shown in NRK-52E (a, b) and NRK-49F (c, d). 
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(C) The mRNA expression of MCP-1 was shown in NRK-52E (a) and 
NRK-49F (b). The symbols are: non-stimulation (None, open bar), TGF-1 
stimulation (Cont, solid bar), pretreatment with 10 or 30mol/l of 
hydroxyfasudil before TGF-1 stimulation (HF-10 or HF-30, hatched bar). 
Results are expressed as mean ± SEM (n= 3). * P < 0.05, ** P < 0.01, *** 
P < 0.001 compared to none, # P < 0.05, ## P < 0.01, ### P < 0.001 
compared to cont. 
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Fig. 17. The mRNA expression of chemokine/cytokines in RAW264.7 
cell 
The mRNA expressions of MCP-1 (A), IL-1 (B), IL-6 (C), and TNF 
(D) were showed in RAW264.7 cell. The symbols are: non-stimulation 
(None, open bar), LPS stimulation (Cont, solid bar), pretreatment with 10 
or 30mol/l of hydroxyfasudil before LPS stimulation (HF-10 or HF-30, 
hatched bar). Results are expressed as mean ± SEM (n= 3). * P < 0.05, *** 
P < 0.001 compared to none. 
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Chapter IV 
Concluding Remarks 
 
These findings indicate that ROCK clearly affects the progression of renal 
interstitial fibrosis, suggesting that ROCK exacerbates renal disease as a 
critical effector molecule.  
In the process of the progression of renal injury, several factors increase 
and stimulate their mutual signaling pathway such as growth factors, 
cytokines, and chemokines. These factors influence the phase 1 (Fig. 1 and 
Fig. 18) in the acute state of injury but in chronic state, these as 
exacerbation factors increase at all times. Given results of the present study, 
ROCK is particularly involved in the phase 1 (as shown the yellow parts in 
Fig. 18), cell activation and injury phase. Therefore, a pharmacological 
inhibition of ROCK affects the progress the whole phases such as EMT, 
myofibroblast activation, proliferation, macrophage infiltration, 
inflammation, and ECM production. 
Moreover, other pathways were affected by fasudil, a ROCK inhibitor in 
mice UUO model. Also, many inflammatory-related genes totally elevated 
after the onset of UUO. Fasudil reduced the deteriorating expression of 
these genes. Thus, the pharmacological inhibition of ROCK 
comprehensively inhibits fibrogenic signaling pathways, 
monocyte/macrophage infiltration, and activation of the inflammatory 
responses in the renal interstitium. 
In conclusion, ROCK inhibitor has the multimodal effects on renal 
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interstitial fibrosis and would be a promising choice for the treatment of 
renal diseases. 
 
 
 
 
Fig. 18. Scheme of renal interstitial fibrosis and target points of ROCK 
inhibitors 
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